- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02582060
Individualizing Hemophilia Prophylaxis Using Thromboelastography
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot study in children and adults with severe hemophilia A that utilizes the TEG/ROTEM to personalize their prophylaxis treatment.
Primary objectives:
• Assess the feasibility of TEG/ROTEM-guided modification of the current prophylaxis regimen for individuals with severe hemophilia A. Specifically, to:
- Test and refine the operational protocol for using TEG/ROTEM to guide factor dosing
- Estimate the proportion of hemophilia A patients whose dose will be modified based on TEG/ROTEM results
- Monitor short term safety of patients whose dose has been modified.
Secondary objectives
- Perform thrombin generation assays to provide additional evidence supporting the TEG/ROTEM-guided dosing.
- Obtain preliminary data on the economic impact of TEG/ROTEM-guided hemophilia A dosing regimens.
- Obtain preliminary data on the potential improvement of subject/family burden resulting from TEG/ROTEM-guided regimen using generic and specific quality of life tools.
The study period will consist of screening, pharmacokinetic (PK) study and follow-up. For subjects whose prophylaxis treatment regimen is modified, the follow-up period will include 3 follow-up clinic visits and 4 follow-up phone calls; these patients will remain on study for approximately 6 months following completion of the PK-study then will have an end of the study visit (visit 9). Subjects whose treatment regimen is not altered will end their study participation after Visit 2 and continuing with their current prophylaxis regimen.
Study endpoints: A safety review will be conducted after the first 6 subjects complete 30 days with the extended prophylaxis treatment. If no safety issues are identified, the study will proceed, and second safety review will be after an additional 8 subjects complete 30 days of extended treatment. If a subject has two or more spontaneous bleeds in 30 days, the subject will be removed from the study. For subjects who did not have bleeds and completed at least 6 months of the study, ongoing prophylactic treatment will be decided by their treating physician.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- CHLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males, 5-70 years, inclusive
- Plasma FVIII activity <1% documented (Laboratory result or MD documentation of Severe Hemophilia A diagnosis)
- Currently prescribed prophylaxis treatment regimen infusing ≥3 times a week
- Willing to alter their prophylaxis treatment regimen per study protocol
Exclusion Criteria:
- Bleeding disorder(s) other than Hemophilia A
- Current inhibitor (>0.6BU)
- Thrombocytopenia (platelet count <100,000K/µL since it can alter TEG®/ROTEM® results)
- Creatinine >2x the upper limit of normal (indicating potential platelet dysfunction)
- Prothrombin time >3 seconds above the upper limit of normal (indicating potential liver dysfunction)
- Any concurrent clinically significant major disease, frequent bleeding pattern or history of non-compliance that, in the opinion of the investigator, would make the subject unsuitable for enrollment
- Participation within the past 30 days in any other clinical study involving investigational drugs
- Planned major surgery within 30 days prior to screening or during the study period
- Current use of any medication known to have effects on the coagulation system
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Severe Hemophilia A Subjects
The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
|
The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of TEG/ROTEM-guided prophylaxis modification for patients, assessed by estimated proportion of patients whose dose is modified.
Time Frame: Ongoing while patients are on study (~ 6 months)
|
A total of 60 patients will be enrolled on this study.
It is expected that less than 25% of these patients will be eligible for dose/schedule modification based on TEG/ROTEM.
|
Ongoing while patients are on study (~ 6 months)
|
Monitoring short-term safety of patients whose dose has been modified, assessed by monitoring number, type, and severity of bleeds.
Time Frame: Ongoing while patients are on study (~ 6 months)
|
The primary endpoint for subject safety will be the occurrence of two serious spontaneous bleeding episodes within 28 days of each other.
|
Ongoing while patients are on study (~ 6 months)
|
Feasibility of TEG/ROTEM-guided prophylaxis modification for patients, assessed by testing and refining operational protocol for using TEG/ROTEM to guide factor dosing.
Time Frame: Ongoing while patients are on study (~ 6 months)
|
Ongoing while patients are on study (~ 6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thrombin generation assay will be performed to provide additional evidence supporting the TEG/ROTEM-guided dosing.
Time Frame: 6 months
|
6 months
|
|
Assessment of direct costs for all subjects whose treatment was modified using factor consumption 6 months before, and the 6 months during study participation.
Time Frame: 1 year
|
Analysis for those subjects who had a modified dosing regimen to determine the per capita reduction in consumption when a modified dosing regimen is achieved.
|
1 year
|
Assessment of indirect costs for all subjects whose treatment was modified using factor consumption 6 months before, and the 6 months during study participation.
Time Frame: 6 months
|
Questionnaire collecting data on time spend on hemophilia-related care per week, caregiver support related to hemophilia, and number of infusions per week.
|
6 months
|
Improvement of subject/family burden as assessed by the Health-Related Quality of Life.
Time Frame: 6 months
|
(HRQoL) Assessments/Analysis
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-00030
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
JW PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A Without InhibitorKorea, Republic of
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
BioMarin PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A With Anti Factor VIIIUnited States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
BayerCompletedHemophilia A; Hemophilia BIsrael
Clinical Trials on Thromboelastography/Thromboelastometry-Guided Treatment Regimen
-
Children's Hospital Los AngelesWithdrawnHemophilia A With Inhibitors
-
University of Texas Southwestern Medical CenterCompletedTraumaUnited States
-
Lithuanian University of Health SciencesCompletedBleeding | Brain Injuries, Traumatic | Coagulation DisorderLithuania
-
Huashan HospitalNot yet recruitingMultidrug Resistant TuberculosisChina
-
Hospital Israelita Albert EinsteinCompletedBleeding | Liver Transplant; Complications | Hemostatic Disorder
-
Xiaodong SunShanghai Zhongshan Hospital; Eye & ENT Hospital of Fudan UniversityUnknownPolypoidal Choroidal VasculopathyChina
-
Tampere University HospitalWithdrawnBlood Loss, Surgical | Coagulation Defect; Acquired | Blood Loss Requiring TransfusionFinland
-
Shandong UniversityUnknownHelicobacter Pylori | Eradication | Therapeutic Duration | Antimicrobial Susceptibility Test
-
xunaRecruitingTime of Hematopoietic ReconstructionChina
-
Young-Hak Kim, MD, PhDRecruitingCoronary DiseaseKorea, Republic of